Suspended
Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
What is being tested
Tazarotene Cream 0.1%
+ Adapalene
Drug
Who is being recruted
Acne Vulgaris+2
+ Sebaceous Gland Diseases
+ Skin Diseases
Over 12 Years
+6 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 4
Interventional
Study Start: October 2007
Summary
Principal SponsorAllergan
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: October 1, 2007
Actual date on which the first participant was enrolled.Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris
Official TitleSafety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
Principal SponsorAllergan
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
165 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 12 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Acne VulgarisSebaceous Gland DiseasesSkin DiseasesSkin and Connective Tissue DiseasesAcneiform Eruptions
Criteria
2 inclusion criteria required to participate
Facial acne vulgaris characterized by the following: 25-100 facial inflammatory lesions (papules plus pustules); and 40 or more non-inflammatory lesions (open/closed comedones)); stable disease, non-rapidly regressing facial acne vulgaris; and, 3 or less facial nodules and/or cysts (diameter of 1cm or greater).
Female subjects of childbearing potential must have a negative urine pregnancy test at baseline and practice reliable method of contraception throughout the study.
4 exclusion criteria prevent from participating
Non-compliance with washout period
Skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris
Allergy or sensitivity to any component of the test medications
Cosmetic or surgical procedure complementary to the treatment of facial acne within 14 days of the baseline visit
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active Comparator1 pea-size amount, QD x 16 weeks
Group II
Active Comparator1 pea-size amount, QD x 16 weeks
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers